Dabigatran

"Dabigatran" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.

Descriptor ID	D000069604
MeSH Number(s)	D03.383.725.192 D03.633.100.103.280
Concept/Terms	Dabigatran Dabigatran N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-beta-alanine BIBR 1048 BIBR 1048 Pradaxa Pradaxa Dabigatran Etexilate Dabigatran Etexilate Etexilate, Dabigatran Dabigatran Etexilate Mesylate Dabigatran Etexilate Mesylate Etexilate Mesylate, Dabigatran Mesylate, Dabigatran Etexilate

Below are MeSH descriptors whose meaning is more general than "Dabigatran".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Pyridines [D03.383.725]
Dabigatran [D03.383.725.192]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 2-Ring [D03.633.100]
Benzimidazoles [D03.633.100.103]
Dabigatran [D03.633.100.103.280]

Below are MeSH descriptors whose meaning is related to "Dabigatran".

Below are MeSH descriptors whose meaning is more specific than "Dabigatran".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Dabigatran" by people in this website by year, and whether "Dabigatran" was a major or minor topic of these publications.

Bar chart showing 73 publications over 15 distinct years, with a maximum of 10 publications in 2011 and 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2007	0	1	1
2009	0	2	2
2010	0	4	4
2011	0	10	10
2012	0	7	7
2013	0	10	10
2014	1	4	5
2015	5	1	6
2016	4	5	9
2017	2	1	3
2018	6	1	7
2019	1	0	1
2020	1	3	4
2021	0	3	3
2022	0	1	1

Below are the most recent publications written about "Dabigatran" by people in Profiles.

Mar PL, Gopinathannair R, Gengler BE, Chung MK, Perez A, Dukes J, Ezekowitz MD, Lakkireddy D, Lip GYH, Miletello M, Noseworthy PA, Reiffel J, Tisdale JE, Olshansky B. Drug Interactions Affecting Oral Anticoagulant Use. Circ Arrhythm Electrophysiol. 2022 06; 15(6):e007956.

View in: PubMed
Mamas MA, Batson S, Pollock KG, Grundy S, Matthew A, Chapman C, Manuel JA, Farooqui U, Mitchell SA. Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation. Am J Cardiol. 2022 03 01; 166:58-64.

View in: PubMed
Chaudhry UA, Ezekowitz MD, Gracely EJ, George WT, Wolfe CM, Harper G, Harper GR. Comparison of Low-Dose Direct Acting Anticoagulant and Warfarin in patients Aged =80 years With Atrial Fibrillation. Am J Cardiol. 2021 08 01; 152:69-77.

View in: PubMed
Millenaar D, Schumacher H, Brueckmann M, Eikelboom JW, Ezekowitz M, Slawik J, Ewen S, Ukena C, Wallentin L, Connolly S, Yusuf S, B?hm M. Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). Am J Cardiol. 2021 06 15; 149:27-35.

View in: PubMed
Wallentin L, Lindb?ck J, Eriksson N, Hijazi Z, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Oldgren J, Siegbahn A. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. Eur Heart J. 2020 11 01; 41(41):4037-4046.

View in: PubMed
B?hm M, Brueckmann M, Eikelboom JW, Ezekowitz M, Fr??dorf M, Hijazi Z, Hohnloser SH, Mahfoud F, Schmieder RE, Schumacher H, Wallentin L, Yusuf S. Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. Eur Heart J. 2020 08 07; 41(30):2848-2859.

View in: PubMed
Sedhom R, Abdelmaseeh P, Megaly M, Asinger R. Use of Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombi: A Systematic Review. Am J Med. 2020 11; 133(11):1266-1273.e6.

View in: PubMed
Shankar S, Saxena A, Saverimuthu A, Perez A, Chandar P, Shenoy MA, Seneviratne C, Kupfer Y. Dabigatran-Associated Diffuse Alveolar Hemorrhage. Am J Ther. 2020 May/Jun; 27(3):e301-e303.

View in: PubMed
Alak A, Hohnloser SH, Fr??dorf M, Reilly P, Ezekowitz M, Healey JS, Brueckmann M, Yusuf S, Connolly SJ. Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial. Europace. 2019 Jul 01; 21(7):1023-1030.

View in: PubMed
Jackson LR, Kim S, Shrader P, Blanco R, Thomas L, Ezekowitz MD, Ansell J, Fonarow GC, Gersh BJ, Go AS, Kowey PR, Mahaffey KW, Hylek EM, Peterson ED, Piccini JP. Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. J Thromb Thrombolysis. 2018 Nov; 46(4):435-439.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement